ReviewPublic health reports (Washington, D.C. : 1974)2025
Hepatitis C Surveillance in the United States: Past, Present, and Future.
Review in Public health reports (Washington, D.C. : 1974), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Data to Monitor Viral Hepatitis Elimination in the United States.Public health reports (Washington, D.C. : 1974) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data from 3 US public health surveillance systems indicate that an estimated 67 400 people acquired hepatitis C virus infections in 2022, 2.2 million adults had hepatitis C during January 2017-March 2020, and 12 717 people died in 2022 from hepatitis C-related causes, despite the availability of curative treatment since 2013. The 3 surveillance systems that provided these data-the National Notifiable Diseases Surveillance System, the National Health and Nutrition Examination Survey, and the National Vital Statistics System-were selected to monitor progress toward elimination of hepatitis C as a public health threat in the United States by 2030. However, some limitations of these surveillance systems compel the use of additional data sources with more timely information for the general population and for populations with higher incidence, prevalence, or mortality of hepatitis C, such as those experiencing homelessness, incarceration, or injection drug use. Commercial laboratories, health systems, and programs serving these populations could provide such data. This topical review of hepatitis C surveillance describes the history, long-term trends, and recent investments in public health surveillance for hepatitis C. Strengthening and modernizing the hepatitis C surveillance workforce and systems, improving data system interoperability, linking complementary data sources, and leveraging multiple data systems can aid in the measurement of public health efforts to meet hepatitis C elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.